BidaskClub upgraded shares of Portola Pharmaceuticals (NASDAQ:PTLA) from a sell rating to a hold rating in a research note issued to investors on Wednesday.
Several other research analysts have also recently issued reports on the company. ValuEngine cut Portola Pharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, March 1st. William Blair reaffirmed a buy rating on shares of Portola Pharmaceuticals in a report on Thursday, March 1st. Morgan Stanley cut Portola Pharmaceuticals from an overweight rating to an equal weight rating and set a $65.00 price target on the stock. in a report on Thursday, March 1st. Oppenheimer set a $67.00 price target on Portola Pharmaceuticals and gave the company a buy rating in a report on Thursday, March 1st. Finally, Credit Suisse Group reaffirmed an outperform rating and issued a $53.00 price target (down previously from $68.00) on shares of Portola Pharmaceuticals in a report on Wednesday, February 21st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $64.90.
Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded down $0.62 during trading hours on Wednesday, reaching $38.43. The company had a trading volume of 1,033,774 shares, compared to its average volume of 1,570,414. Portola Pharmaceuticals has a 1 year low of $30.10 and a 1 year high of $67.10. The company has a market capitalization of $2,513.01, a PE ratio of -8.04 and a beta of 1.34. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.92 and a current ratio of 5.94.
In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of Portola Pharmaceuticals stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 5.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. grew its position in Portola Pharmaceuticals by 69.1% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 7,452 shares of the biopharmaceutical company’s stock worth $403,000 after purchasing an additional 3,044 shares in the last quarter. Harbor Advisors LLC purchased a new position in Portola Pharmaceuticals during the 4th quarter worth approximately $348,000. Legal & General Group Plc grew its position in Portola Pharmaceuticals by 19.0% during the 3rd quarter. Legal & General Group Plc now owns 22,464 shares of the biopharmaceutical company’s stock worth $1,210,000 after purchasing an additional 3,594 shares in the last quarter. Prudential Financial Inc. grew its position in Portola Pharmaceuticals by 36.8% during the 3rd quarter. Prudential Financial Inc. now owns 123,316 shares of the biopharmaceutical company’s stock worth $6,663,000 after purchasing an additional 33,180 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in Portola Pharmaceuticals by 18.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 270,471 shares of the biopharmaceutical company’s stock worth $14,614,000 after purchasing an additional 42,284 shares in the last quarter. Hedge funds and other institutional investors own 87.52% of the company’s stock.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.